Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Coating of silicone with mannoside-PAMAM dendrimers to enhance formation of non-pathogenic Escherichia coli biofilms against colonization of uropathogens.

Zhu Z, Yu F, Chen H, Wang J, Lopez AI, Chen Q, Li S, Long Y, Darouiche RO, Hull RA, Zhang L, Cai C.

Acta Biomater. 2017 Dec;64:200-210. doi: 10.1016/j.actbio.2017.10.008. Epub 2017 Oct 9.

PMID:
29024820
2.

Left atrial appendage morphology and risk of stroke following pulmonary vein isolation for drug-refractory atrial fibrillation in low CHA2DS2Vasc risk patients.

Kelly FR, Hull RA, Arrey-Mbi TB, Williams MU, Lee JS, Slim AM, Thomas DM.

BMC Cardiovasc Disord. 2017 Feb 28;17(1):70. doi: 10.1186/s12872-017-0504-7.

3.

In vitro activity and durability of a combination of an antibiofilm and an antibiotic against vascular catheter colonization.

Mansouri MD, Hull RA, Stager CE, Cadle RM, Darouiche RO.

Antimicrob Agents Chemother. 2013 Jan;57(1):621-5. doi: 10.1128/AAC.01646-12. Epub 2012 Oct 31.

4.

Bacterial interference for prevention of urinary tract infection.

Darouiche RO, Hull RA.

Clin Infect Dis. 2012 Nov 15;55(10):1400-7. doi: 10.1093/cid/cis639. Epub 2012 Jul 24. Review. No abstract available.

PMID:
22828592
5.

Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder.

Darouiche RO, Green BG, Donovan WH, Chen D, Schwartz M, Merritt J, Mendez M, Hull RA.

Urology. 2011 Aug;78(2):341-6. doi: 10.1016/j.urology.2011.03.062. Epub 2011 Jun 17.

PMID:
21683991
6.

Comparison of Escherichia coli strains as agents for bacterial interference.

Darouiche RO, Riosa S, Hull RA.

Infect Control Hosp Epidemiol. 2010 Jun;31(6):659-61. doi: 10.1086/653070. No abstract available.

PMID:
20426581
7.

Increased expression of type-1 fimbriae by nonpathogenic Escherichia coli 83972 results in an increased capacity for catheter adherence and bacterial interference.

Trautner BW, Cevallos ME, Li H, Riosa S, Hull RA, Hull SI, Tweardy DJ, Darouiche RO.

J Infect Dis. 2008 Sep 15;198(6):899-906. doi: 10.1086/591093.

8.

Discovery and characterization of novel, potent, non-peptide parathyroid hormone-1 receptor antagonists.

McDonald IM, Austin C, Buck IM, Dunstone DJ, Gaffen J, Griffin E, Harper EA, Hull RA, Kalindjian SB, Linney ID, Low CM, Patel D, Pether MJ, Raynor M, Roberts SP, Shaxted ME, Spencer J, Steel KI, Sykes DA, Wright PT, Xun W.

J Med Chem. 2007 Oct 4;50(20):4789-92. Epub 2007 Sep 12.

PMID:
17850061
9.

Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion.

McDonald IM, Black JW, Buck IM, Dunstone DJ, Griffin EP, Harper EA, Hull RA, Kalindjian SB, Lilley EJ, Linney ID, Pether MJ, Roberts SP, Shaxted ME, Spencer J, Steel KI, Sykes DA, Walker MK, Watt GF, Wright L, Wright PT, Xun W.

J Med Chem. 2007 Jun 28;50(13):3101-12. Epub 2007 May 31.

PMID:
17536796
10.

Coating urinary catheters with an avirulent strain of Escherichia coli as a means to establish asymptomatic colonization.

Trautner BW, Hull RA, Thornby JI, Darouiche RO.

Infect Control Hosp Epidemiol. 2007 Jan;28(1):92-4. Epub 2006 Dec 29.

11.

Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist.

Gerskowitch VP, Hodge J, Hull RA, Shankley NP, Kalindjian SB, McEwen J, Black JW.

Br J Clin Pharmacol. 2007 May;63(5):618-22. Epub 2006 Oct 17.

12.

Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.

McDonald IM, Austin C, Buck IM, Dunstone DJ, Griffin E, Harper EA, Hull RA, Kalindjian SB, Linney ID, Low CM, Pether MJ, Spencer J, Wright PT, Adatia T, Bashall A.

J Med Chem. 2006 Apr 6;49(7):2253-61.

PMID:
16570921
13.

Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists.

Buck IM, Black JW, Cooke T, Dunstone DJ, Gaffen JD, Griffin EP, Harper EA, Hull RA, Kalindjian SB, Lilley EJ, Linney ID, Low CM, McDonald IM, Pether MJ, Roberts SP, Shankley NP, Shaxted ME, Steel KI, Sykes DA, Tozer MJ, Watt GF, Walker MK, Wright L, Wright PT.

J Med Chem. 2005 Nov 3;48(22):6803-12.

PMID:
16250639
14.

Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial.

Darouiche RO, Thornby JI, Cerra-Stewart C, Donovan WH, Hull RA.

Clin Infect Dis. 2005 Nov 15;41(10):1531-4. Epub 2005 Oct 13.

PMID:
16231269
15.

Colicins prevent colonization of urinary catheters.

Trautner BW, Hull RA, Darouiche RO.

J Antimicrob Chemother. 2005 Aug;56(2):413-5. Epub 2005 Jun 24.

16.

Prevention of catheter-associated urinary tract infection.

Trautner BW, Hull RA, Darouiche RO.

Curr Opin Infect Dis. 2005 Feb;18(1):37-41. Review.

17.

Escherichia coli 83972 inhibits catheter adherence by a broad spectrum of uropathogens.

Trautner BW, Hull RA, Darouiche RO.

Urology. 2003 May;61(5):1059-62.

18.

Role of type 1 fimbria- and P fimbria-specific adherence in colonization of the neurogenic human bladder by Escherichia coli.

Hull RA, Donovan WH, Del Terzo M, Stewart C, Rogers M, Darouiche RO.

Infect Immun. 2002 Nov;70(11):6481-4.

19.
20.
21.

Pilot trial of bacterial interference for preventing urinary tract infection.

Darouiche RO, Donovan WH, Del Terzo M, Thornby JI, Rudy DC, Hull RA.

Urology. 2001 Sep;58(3):339-44.

PMID:
11549475
22.

Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.

Low CM, Black JW, Broughton HB, Buck IM, Davies JM, Dunstone DJ, Hull RA, Kalindjian SB, McDonald IM, Pether MJ, Shankley NP, Steel KI.

J Med Chem. 2000 Sep 21;43(19):3505-17.

PMID:
11000005
23.

Bacterial interference for prevention of urinary tract infection: an overview.

Darouiche RO, Hull RA.

J Spinal Cord Med. 2000 Summer;23(2):136-41. Review.

PMID:
10914355
24.

Virulence properties of Escherichia coli 83972, a prototype strain associated with asymptomatic bacteriuria.

Hull RA, Rudy DC, Donovan WH, Wieser IE, Stewart C, Darouiche RO.

Infect Immun. 1999 Jan;67(1):429-32.

26.

Identification of a Klebsiella pneumoniae strain associated with nosocomial urinary tract infection.

Kil KS, Darouiche RO, Hull RA, Mansouri MD, Musher DM.

J Clin Microbiol. 1997 Sep;35(9):2370-4.

27.
28.

Analysis of the variation in the action of L-365,260 at CCKB/gastrin receptors in rat, guinea-pig and mouse isolated gastric tissue assays.

Roberts SP, Harper EA, Watt GF, Gerskowitch VP, Hull RA, Shankley NP, Black JW.

Br J Pharmacol. 1996 Aug;118(7):1779-89.

30.

The use of receptor desensitization to analyse CCKA and CCKB/gastrin receptors coupled to contraction in guinea-pig stomach muscle.

Bishop LA, Gerskowitch VP, Hull RA, Shankley NP, Black JW.

Br J Pharmacol. 1995 Jan;114(2):339-48.

31.

Molecular cloning of adhesion genes.

Hull SI, Hull RA.

Methods Enzymol. 1995;253:258-69. No abstract available.

PMID:
7476391
32.

Effect of pap copy number and receptor specificity on virulence of fimbriated Escherichia coli in a murine urinary tract colonization model.

Hull RA, Nowicki B, Kaul A, Runyan R, Svanborg C, Hull SI.

Microb Pathog. 1994 Aug;17(2):79-86.

PMID:
7861959
33.

Alanine-scanning mutagenesis reveals residues involved in binding of pap-3-encoded pili.

Klann AG, Hull RA, Palzkill T, Hull SI.

J Bacteriol. 1994 Apr;176(8):2312-7.

34.
35.
36.

2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP)--a selective cholecystokinin CCKA-receptor antagonist.

Hull RA, Shankley NP, Harper EA, Gerkowitch VP, Black JW.

Br J Pharmacol. 1993 Mar;108(3):734-40.

37.

Sequences of the genes encoding the minor tip components of Pap-3 pili of Escherichia coli.

Klann AG, Hull RA, Hull SI.

Gene. 1992 Sep 21;119(1):95-100.

PMID:
1356886
39.
40.

Inotropic polyazapentalene sulmazole analogues.

Barraclough P, Black JW, Cambridge D, Firmin D, Gerskowitch VP, Glen RC, Giles H, Gillam JM, Hull RA, Iyer R, et al.

Arch Pharm (Weinheim). 1992 Apr;325(4):225-34.

PMID:
1530455
41.

Molecular cloning and expression of the 01 rfb region from a pyelonephritic Escherichia coli 01:H1:K7.

Ding MJ, Svanborg C, Haraguchi GE, Hull RA, Hull SI.

Microb Pathog. 1991 Nov;11(5):379-85.

PMID:
1726183
42.
43.

Genetic characterization of the O4 polysaccharide gene cluster from Escherichia coli.

Haraguchi GE, Zähringer U, Jann B, Jann K, Hull RA, Hull SI.

Microb Pathog. 1991 May;10(5):351-61.

PMID:
1721674
44.

Cloning and expression in Escherichia coli of a gene encoding proline oxidase of Serratia marcescens.

Leranoz AM, Fusté MC, Viñas M, Hull RA, Williams RP.

Microbios. 1991;67(271):87-94.

PMID:
1656168
45.

pap-2-encoded fimbriae adhere to the P blood group-related glycosphingolipid stage-specific embryonic antigen 4 in the human kidney.

Karr JF, Nowicki BJ, Truong LD, Hull RA, Moulds JJ, Hull SI.

Infect Immun. 1990 Dec;58(12):4055-62.

46.

Cardiotonic 'C' ring modified isomazole analogues.

Barraclough P, Black JW, Cambridge D, Demaine DA, Gerskowitch VP, Giles H, Hill AP, Hull RA, Lyer R, King WR, et al.

Arch Pharm (Weinheim). 1990 Aug;323(8):507-12.

PMID:
2278517
47.

Inotropic activities of imidazopyridines.

Barraclough P, Black JW, Cambridge D, Gerskowitch VP, Hull RA, Lyer R, King WR, Kneen CO, Nobbs MS, Shah GP, et al.

Arch Pharm (Weinheim). 1990 Aug;323(8):501-5.

PMID:
2278516
48.

Inotropic "A" ring substituted sulmazole and isomazole analogues.

Barraclough P, Black JW, Cambridge D, Collard D, Firmin D, Gerskowitch VP, Glen RC, Giles H, Hill AP, Hull RA, et al.

J Med Chem. 1990 Aug;33(8):2231-9.

PMID:
2165165
49.
50.

Distribution of the P-associated-pilus (pap) region among Escherichia coli from natural sources: evidence for horizontal gene transfer.

Plos K, Hull SI, Hull RA, Levin BR, Orskov I, Orskov F, Svanborg-Edén C.

Infect Immun. 1989 May;57(5):1604-11.

Supplemental Content

Support Center